Parasite Chemotherapy

The research area of the Parasite Chemotherapy group comprises three main areas:

 

Activities in drug discovery and development for protozoan parasites and helminths increased significantly during the last 2 years. Our group has a screening mandate from the Medicines for Malaria Venture (MMV) Foundation and became the main centre for WHO/TDR for in vitro screening against protozoan parasites.

Besides working on new drugs, the group also collaborates with African partner institutes in the Eastern Africa Network for Trypanosomosis (EANETT) in the area of sleeping sickness research and control. The Swiss Agency for Development and Co-operation (SDC) awarded the network a second phase of support for 2004–2006. A major goal for this phase will be to involve the network in international activities with access to additional funding.

A third element of activities deals with studies of trypanosome transmission through the tsetse fly vector to gain more knowledge about the life cycle of the parasite and the function of certain surface proteins.